FAST-IRM for HCC suRveillance in pAtients With High risK of Liver Cancer.
Randomized Study Evaluating the Cost Impact and Effectiveness of Systematic Liver Fast-MRI Surveillance for Early-stage Hepatocellular Carcinoma in High-risk Patients Included in Ultrasound Surveillance Programs
Assistance Publique - Hôpitaux de Paris
944 participants
Nov 23, 2022
INTERVENTIONAL
Conditions
Summary
Intro: Hepatocellular carcinoma (HCC) is the 6th leading cause of cancer worldwide. In France, more than 10,000 new cases are identified each year. The latter occur in 85% of cases in cirrhosis, the most frequent causes of which are excessive alcohol consumption, metabolic syndrome or HBV/HCV infection. Patients with cirrhosis justify being included in monitoring programs involving the performance of a semi-annual liver ultrasound (US) in order to detect HCC eligible for curative treatment (liver resection or percutaneous ablation). This practice is considered to be cost-effective in the event of an annual incidence of HCC\> 1.5%. US in this context has a low sensitivity for the detection of HCC at the very early stage and the following observations have been made in the last 20 years: * The rate of patients detected at early stage BCLC 0 is around 30% by ultrasound * The rate of patients included in surveillance programs detected with advanced HCC eligible for palliative treatment is around 20% * Reducing the periodicity of liver ultrasounds from 6 to 3 months does not improve these results. In parallel, liver MRI has been evaluated as a tool for the early detection of HCC. Its performance for the detection of HCC at the very early stage exceeds 80%. However, due to the higher cost compared to US, it was estimated that its use in screening context would only be cost effective in the event of an annual incidence\> 3%. In addition, the practice of these expensive and long-lasting MRIs (30 to 45 minutes) can be optimized by carrying out abbreviated MRI protocols" or Fast-MRI: short protocols (\<10 minutes), based on the sequences with the better detection sensitivities (Se\> 83%). The hypothesis is that Fast-MRI used as a screening examination in patients at high risk of HCC (\> 3% per year) could increase the rates of patients detected at an early stage accessible to curative treatment and demonstrate its cost-effectiveness in this population. Hypothesis/Objective: The main objective is to assess the cost / QALY and / patient detected with an early HCC BCLC 0 (single tumor \<2cm) by semi-annual monitoring by liver US and Fast-MRI, compared to conventional semi-annual monitoring by liver US alone in patients with cirrhosis and an anticipated HCC incidence\>3%. Conclusion: If positive, this trial could modify international practice guidelines and set MRI as the optimal tool for early HCC detection in high-risk patients.
Eligibility
Inclusion Criteria10
- Age ≥ 18 years
- Patient enrolled in a screening program for at least 6 months in a tertiary hepatology center
- Cirrhosis histologically proven or unequivocally suggested by non-invasive tests
- Absence of HCC on imaging less than 3 months o
- Liver parenchyma explorable by ultrasound
- Child-Pugh A or B
- Cirrhosis of non-viral or viral B/C cause controlled/healed
- With an estimated annual risk of HCC\>3%
- Written informed consent
- Affiliation to a social security system
Exclusion Criteria10
- Child-Pugh C score
- Active hepatitis B or C
- Estimated annual risk of HCC\<3%
- No prior enrollment in a screening program
- Contraindication to Fast-MRI
- Non-echogenic patient
- Patient deprived of liberty
- Patient under legal protection
- Pregnant or breastfeeding woman
- Patient on AME (state medical aid)
Interventions
Half-yearly liver ultrasound and fast-MRI
Half-yearly liver ultrasound
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05095714